Ugonma Chukwueke

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Ugonma Chukwueke sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Ugonma Chukwueke: 1 sponsored US clinical trial, 1 recruiting.

Ugonma Chukwueke sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Recurrent Glioblastoma, with 1 trials.

Mid-pack sponsor footprint

Ugonma Chukwueke is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Ugonma Chukwueke pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Recurrent Glioblastoma (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Ugonma Chukwueke: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Ugonma Chukwueke sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Ugonma Chukwueke1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Ugonma Chukwueke sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ugonma Chukwueke sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Ugonma Chukwueke page

1 registered trials is a research-attention snapshot, not an endorsement of Ugonma Chukwueke or any single study.

  • 1 of Ugonma Chukwueke's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Recurrent Glioblastoma is the condition Ugonma Chukwueke studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Recurrent Glioblastoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ugonma Chukwueke pipeline card: 1 registered trials from official public datasets.Report a data error.